Drugs / CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT
CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03315078 | Apr 2012 → Dec 2022 | combined immunodeficiency, X-linked | National Institute of Allergy and Infectious Diseases (NIAID) | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03315078 ↗ |
| Action | Restore | “restoring immune function” NCT03315078 ↗ |
| Modality | Cell therapy | “gene-modified CD34+ HSCs” NCT03315078 ↗ |
| Route | Intravenous | “Administered by intravenous (IV) infusion” NCT03315078 ↗ |